125 related articles for article (PubMed ID: 27093760)
1. Skeletal Health Part 2: Development of a Nurse Practitioner Bone Support Clinic for Urologic Patients.
Turner B; Ali S; Drudge-Coates L; Pati J; Nargund V; Wells P
Urol Nurs; 2016; 36(1):22-6. PubMed ID: 27093760
[TBL] [Abstract][Full Text] [Related]
2. Skeletal Health Part 1: Overview Of Bone Health and Management In the Cancer Setting.
Turner B; Ali S; Drudge-Coates L; Pati J; Nargund V; Wells P
Urol Nurs; 2016; 36(1):17-21, 26. PubMed ID: 27093759
[TBL] [Abstract][Full Text] [Related]
3. Treatment of bone metastases in urologic malignancies.
Froehner M; Hölscher T; Hakenberg OW; Wirth MP
Urol Int; 2014; 93(3):249-56. PubMed ID: 25115989
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate therapy for metastatic bone disease: the pivotal role of nurses in patient education.
Fitch MI; Maxwell C
Oncol Nurs Forum; 2008 Jul; 35(4):709-13. PubMed ID: 18591175
[TBL] [Abstract][Full Text] [Related]
5. Bone metastases and bone loss medical treatment in prostate cancer patients.
Safriadi F
Acta Med Indones; 2013 Jan; 45(1):76-80. PubMed ID: 23585414
[TBL] [Abstract][Full Text] [Related]
6. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer.
Carter JA; Botteman MF
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):425-37. PubMed ID: 22540167
[TBL] [Abstract][Full Text] [Related]
7. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy.
Saad F; Sternberg CN
Nat Clin Pract Urol; 2007 Feb; 4 Suppl 1():S3-13. PubMed ID: 17264863
[TBL] [Abstract][Full Text] [Related]
8. Role of the nurse in preserving patients' independence.
Maxwell C
Eur J Oncol Nurs; 2007; 11 Suppl 2():S38-41. PubMed ID: 17768093
[TBL] [Abstract][Full Text] [Related]
9. The role of nurses in preserving patients' functional independence: Zoledronic acid--evidence and experience in metastatic bone disease.
Fitch MI
Eur J Oncol Nurs; 2007; 11 Suppl 2():S27. PubMed ID: 17804295
[No Abstract] [Full Text] [Related]
10. Taking the lead: sharing best practice in intravenous bisphosphonate use in urological cancers.
Jensen BT; Dielenseger P; Drudge-Coates L; Flynn K; Hieronymi S; Erik van Muilekom HA; Pieters R; Voss LB
Eur J Oncol Nurs; 2012 Feb; 16(1):42-53. PubMed ID: 21429796
[TBL] [Abstract][Full Text] [Related]
11. Why a carefully designed, nurse-led intervention failed to meet expectations: the case of the Care Programme for Palliative Radiotherapy.
Vahedi Nikbakht-Van de Sande CV; Braat C; Visser AP; Delnoij DM; van Staa AL
Eur J Oncol Nurs; 2014 Apr; 18(2):151-8. PubMed ID: 24365719
[TBL] [Abstract][Full Text] [Related]
12. Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
Pouessel D; Culine S
Anticancer Drugs; 2012 Jan; 23(1):141-2. PubMed ID: 21934600
[TBL] [Abstract][Full Text] [Related]
13. New anti-resorptives and antibody mediated anti-resorptive therapy.
Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
[TBL] [Abstract][Full Text] [Related]
14. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
15. Effects of bone-targeted agents on cancer progression and mortality.
Coleman R; Gnant M; Morgan G; Clezardin P
J Natl Cancer Inst; 2012 Jul; 104(14):1059-67. PubMed ID: 22752060
[TBL] [Abstract][Full Text] [Related]
16. Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration.
Schmitz-Dräger BJ; Weiss C; Ebert T; Dörsam J; Bismarck E
Urol Int; 2013; 90(3):329-33. PubMed ID: 23407093
[TBL] [Abstract][Full Text] [Related]
17. New developments for treatment and prevention of bone metastases.
Body JJ
Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
Miki T; Okihara K
Nihon Rinsho; 2007 Nov; 65 Suppl 9():632-5. PubMed ID: 18161177
[No Abstract] [Full Text] [Related]
19. Treatment options for breast cancer and bone metastases.
Pecherstorfer M
Womens Health (Lond); 2009 Mar; 5(2):149-63. PubMed ID: 19245353
[TBL] [Abstract][Full Text] [Related]
20. Long-term benefits versus side-effects from bone-targeted therapies for cancer patients: minimizing risk while maximizing benefits.
Jacobs C; Ng T; Ong M; Clemons M
Curr Opin Support Palliat Care; 2014 Dec; 8(4):420-8. PubMed ID: 25121618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
